Synergy. Should it determine antibiotic selection in neutropenic patients?

Bodey, Gerald P.

doi:10.1001/archinte.145.11.1964

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When administered as single agents, aminoglycosides yielded disappointing results in the treatment of infections in patients with cancer, particularly against documented bacteremia due to gram-negative organisms [54,55]. The addition of a b-lactam antibiotic to the regimen improved the outcomes of these infections dramatically [56].…”

Section: Infections In Patients With Cancermentioning

confidence: 99%

The Importance of Bactericidal Drugs: Future Directions in Infectious Disease

Finberg

Moellering

Tally

et al. 2004

Clinical Infectious Diseases

184

114

View full text Add to dashboard Cite

The bulk of the evidence supports the concept that, in treating endocarditis and meningitis, it is important to use antibacterial agents with in vitro bactericidal activity. This conclusion is based on both human and animal data. The data to support bactericidal drugs' superiority to bacteriostatic drugs do not exist for most other clinical situations, and animal models do not support this concept in some situations. Clinicians should be aware that drugs that are bacteriostatic for one organism may in fact be bactericidal for another organism or another strain of the same organism.

show abstract

Section: Infections In Patients With Cancermentioning

confidence: 99%

The Importance of Bactericidal Drugs: Future Directions in Infectious Disease

Finberg

Moellering

Tally

et al. 2004

Clinical Infectious Diseases

184

114

View full text Add to dashboard Cite

show abstract

“…Immunosuppressed patients can contribute less to infection resolution from their own immune system. Early trials from the 1970s demonstrated that the bactericidal combination of β-lactams plus aminoglycosides was superior to treatment with aminoglycoside alone [16,17]. Most of the recent studies in neutropenic patients have used bactericidal drugs, alone or in combination, unless there is specific intolerance.…”

Section: Bactericidal Drugs and Resistancementioning

confidence: 99%

The advance of bacterididal drugs in the treatment of infection

Alder

Eisenstein²

2004

Curr Infect Dis Rep

View full text Add to dashboard Cite

Comparison of the serum bactericidal activity of ceftriaxone/ piperacillin and ceftriaxone/netilmicin

Machka¹,

Röbl²,

Braveny³

1986

Eur. J, Clin. Microbiol.

View full text Add to dashboard Cite

The serum bactericidal activities of ceftriaxone, netilmicin, piperacillin and the combinations of ceftriaxone with each of the two other antibiotics were compared 1, 4 and 24 h after i.v. infusion in six volunteers. One hundred and one clinical isolates were used, including Staphylococcus aureus, Pseudomonas aeruginosa and various Enterobacteriaceae. The highest bactericidal titers were found against the Enterobacteriaceae, geometric means of 1:741 and 1:851 being obtained for ceftriaxone/netilmicin and ceftriaxone/piperacillin respectively. Against Staphylococcus aureus the geometric mean bactericidal titers of ceftriaxone/piperacillin (1:105) were markedly higher than ceftriaxone/netilmicin (1:35). Low bactericidal activity was exhibited by all drugs and combinations tested against Pseudomonas aeruginosa; a geometric mean bactericidal titer of 1:4.6 was achieved. The serum bactericidal activity of the double beta-lactam combinations was found to be at least equal to that of the combination containing a cephalosporin and an aminoglycoside.

show abstract

Synergy. Should it determine antibiotic selection in neutropenic patients?

Cited by 4 publications

References 17 publications

The Importance of Bactericidal Drugs: Future Directions in Infectious Disease

The Importance of Bactericidal Drugs: Future Directions in Infectious Disease

The advance of bacterididal drugs in the treatment of infection

Comparison of the serum bactericidal activity of ceftriaxone/ piperacillin and ceftriaxone/netilmicin

Contact Info

Product

Resources

About